The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Viekira Pak™ (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets)

What types of adverse reactions were reported when taking Viekira Pak™?

In clinical studies, those receiving Viekira Pak™ with ribavirin, the most commonly reported adverse reactions (>10% of subjects) were fatigue, nausea, pruritus (severe itching), other skin reactions, insomnia and asthenia (weakness).

In subjects receiving Viekira Pak™ without ribavirin, the most commonly reported adverse reactions ( ≥5% of subjects) were nausea, pruritus and insomnia.

Last Updated: May 2015
 

Advances in Medications to Treat Hepatitis C. http://hepc.liverfoundation.org/treatment/the-basics-about-hepatitis-c-treatment/advances-in-medications/, American Liver Foundation. Retrieved May 7, 2015.

Benefits Verification. https://www.viekira.com/benefits-verification, Viekira.com. Retrieved May 7, 2015.

FDA Approves Viekira Pak to Treat Hepatitis C. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427530.htm, U.S. Food and Drug Administration. Retrieved May 7, 2015.

Highlights of Prescribing Information - Viekira Pak. http://www.rxabbvie.com/pdf/viekirapak_pi.pdf, AbbVie, Inc. Retrieved May 7, 2015.

proCeed Support Program. https://www.viekira.com/proceed-support, Viekira.com. Retrieved May 7, 2015.

Viekira Pak (ombitasvir/paritaprevir/ritonavir tablets; dasabuvir tablets). https://www.viekira.com/, Viekira.com. Retrieved May 7, 2015.